Dexcom Stock Nears 52-Week High After Q2 Earnings Beat

Key Facts

Amid the ongoing expansion in the advanced medical device market, Dexcom reported strong Q2 2026 financial results that exceeded analyst expectations. The company posted revenue of $1.31 billion, a 13.1% increase year-over-year, while earnings per share reached $0.70. This positive performance was primarily driven by surging demand for the company's flagship continuous glucose monitoring products, including the G7 and G6 systems.

Per market data, DXCM stock is currently trading near its 52-week high, reflecting investor confidence in the company's growth trajectory. The beat on both top and bottom-line estimates has solidified the stock's position within the healthcare sector, although a high price-to-earnings ratio remains a point of discussion among analysts evaluating further immediate upside potential.

Dexcom stock stood at $91.06 at the close of August 24, 2026, having reached a day high of $92.59. Looking ahead at the economic calendar, traders are monitoring the FOMC Minutes scheduled for August 19 for broader monetary policy signals that could impact growth-oriented medical technology equities.